Literature DB >> 26439151

Conventional Therapy in Adults With XLH Improves Dental Manifestations, But Not Enthesopathy.

Michael J Econs1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26439151      PMCID： PMC4596048          DOI： 10.1210/jc.2015-3229

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  19 in total

1.  Conventional Therapy in Adults With X-Linked Hypophosphatemia: Effects on Enthesopathy and Dental Disease.

Authors:  Jessica Connor; Elizabeth A Olear; Karl L Insogna; Lee Katz; Suher Baker; Raghbir Kaur; Christine A Simpson; John Sterpka; Robert Dubrow; Jane H Zhang; Thomas O Carpenter
Journal:  J Clin Endocrinol Metab       Date:  2015-07-15       Impact factor: 5.958

2.  Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status.

Authors:  Thomas O Carpenter; Karl L Insogna; Jane H Zhang; Bruce Ellis; Sherril Nieman; Christine Simpson; Elizabeth Olear; Caren M Gundberg
Journal:  J Clin Endocrinol Metab       Date:  2010-08-04       Impact factor: 5.958

Review 3.  Tooth dentin defects reflect genetic disorders affecting bone mineralization.

Authors:  S Opsahl Vital; C Gaucher; C Bardet; P S Rowe; A George; A Linglart; C Chaussain
Journal:  Bone       Date:  2012-01-26       Impact factor: 4.398

Review 4.  A clinician's guide to X-linked hypophosphatemia.

Authors:  Thomas O Carpenter; Erik A Imel; Ingrid A Holm; Suzanne M Jan de Beur; Karl L Insogna
Journal:  J Bone Miner Res       Date:  2011-05-02       Impact factor: 6.741

5.  Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations.

Authors:  Erik A Imel; Linda A DiMeglio; Siu L Hui; Thomas O Carpenter; Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2010-02-15       Impact factor: 5.958

6.  Mineralizing enthesopathy is a common feature of renal phosphate-wasting disorders attributed to FGF23 and is exacerbated by standard therapy in hyp mice.

Authors:  Andrew C Karaplis; Xiuying Bai; Jean-Pierre Falet; Carolyn M Macica
Journal:  Endocrinology       Date:  2012-10-04       Impact factor: 4.736

7.  Dentin structure in familial hypophosphatemic rickets: benefits of vitamin D and phosphate treatment.

Authors:  C Chaussain-Miller; C Sinding; D Septier; M Wolikow; M Goldberg; M Garabedian
Journal:  Oral Dis       Date:  2007-09       Impact factor: 3.511

8.  Survey of the enthesopathy of X-linked hypophosphatemia and its characterization in Hyp mice.

Authors:  Guoying Liang; Lee D Katz; Karl L Insogna; Thomas O Carpenter; Carolyn M Macica
Journal:  Calcif Tissue Int       Date:  2009-07-17       Impact factor: 4.333

9.  Dosage effect of a Phex mutation in a murine model of X-linked hypophosphatemia.

Authors:  Shoji Ichikawa; Amie K Gray; Emmanuel Bikorimana; Michael J Econs
Journal:  Calcif Tissue Int       Date:  2013-05-23       Impact factor: 4.333

10.  Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets.

Authors:  Uri S Alon; Rachel Levy-Olomucki; Wayne V Moore; Jason Stubbs; Shiguang Liu; L Darryl Quarles
Journal:  Clin J Am Soc Nephrol       Date:  2008-02-06       Impact factor: 8.237
View more
  4 in total

Review 1.  Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia.

Authors:  Andrea Trombetti; Nasser Al-Daghri; Maria Luisa Brandi; Jorge B Cannata-Andía; Etienne Cavalier; Manju Chandran; Catherine Chaussain; Lucia Cipullo; Cyrus Cooper; Dieter Haffner; Pol Harvengt; Nicholas C Harvey; Muhammad Kassim Javaid; Famida Jiwa; John A Kanis; Andrea Laslop; Michaël R Laurent; Agnès Linglart; Andréa Marques; Gabriel T Mindler; Salvatore Minisola; María Concepción Prieto Yerro; Mario Miguel Rosa; Lothar Seefried; Mila Vlaskovska; María Belén Zanchetta; René Rizzoli
Journal:  Nat Rev Endocrinol       Date:  2022-04-28       Impact factor: 43.330

Review 2.  FGF23 and its role in X-linked hypophosphatemia-related morbidity.

Authors:  Signe Sparre Beck-Nielsen; Zulf Mughal; Dieter Haffner; Ola Nilsson; Elena Levtchenko; Gema Ariceta; Carmen de Lucas Collantes; Dirk Schnabel; Ravi Jandhyala; Outi Mäkitie
Journal:  Orphanet J Rare Dis       Date:  2019-02-26       Impact factor: 4.123

Review 3.  Multidisciplinary patient care in X-linked hypophosphatemic rickets: one challenge, many perspectives.

Authors:  Adalbert Raimann; Gabriel T Mindler; Roland Kocijan; Katrin Bekes; Jochen Zwerina; Gabriele Haeusler; Rudolf Ganger
Journal:  Wien Med Wochenschr       Date:  2020-01-28

4.  Diagnosis and management of X-linked hypophosphatemia in children and adolescent in the Gulf Cooperation Council countries.

Authors:  Fahad Al Juraibah; Elham Al Amiri; Mohammed Al Dubayee; Jamal Al Jubeh; Hessa Al Kandari; Afaf Al Sagheir; Adnan Al Shaikh; Salem A Beshyah; Asma Deeb; Abdelhadi Habeb; Manal Mustafa; Hanaa Zidan; M Zulf Mughal
Journal:  Arch Osteoporos       Date:  2021-03-04       Impact factor: 2.617
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.